Aethlon Medical, Inc. (AEMD) is a leading brand that develops innovative immunotherapeutic technologies to combat cancer and infectious diseases. Their flagship product, the Hemopurifier®, is a groundbreaking technology designed to rapidly deplete cancer-promoting exosomes and circulating viruses.

Recognized by the United States Food and Drug Administration (FDA) as a Breakthrough Device, the Hemopurifier® offers hope for individuals with advanced or metastatic cancer who are unresponsive or intolerant to standard treatments, as well as those facing life-threatening viruses without approved therapies. Aethlon Medical's mission is to provide effective solutions for patients where traditional therapies fall short. Currently, they are conducting a clinical trial targeting Sars-CoV-2 in India, and soon, they will be launching an oncology clinical trial in Australia.

With a dedicated team of experts, Aethlon Medical is revolutionizing the field of immunotherapy and making significant strides in the fight against cancer and infectious diseases